For the quarter ending 2025-10-31.
| Income Statement | 2025-10-31 | 2025-07-31 | ||
|---|---|---|---|---|
| Research and development expenses | 6,683,643 | 5,317,669.5* | ||
| General and administrative expenses | 1,639,300 | 1,483,531.25* | ||
| Total operating expenses | 8,322,943 | 6,801,200.75 | ||
| Operating loss | -8,322,943 | -6,801,200.75* | ||
| Financial income, net | 158,646 | 28,627.75* | ||
| Change in fair value of the warrant liability | 69,201 | -189,591* | ||
| Share of loss on equity investment | -44,830 | -56,053* | ||
| Net loss for the period | -8,278,328 | -6,639,035* | ||
| Net loss attributable to non-controlling interest | -80,763 | -61,068.25* | ||
| Net loss for the period attributable to briacell | -8,197,565 | -6,577,966.75 | ||
| Basic EPS | -4.35 | -15.547 | ||
| Diluted EPS | -4.35 | -15.547 | ||
| Basic Average Shares | 1,883,906 | 423,114 | ||
| Diluted Average Shares | 1,883,906 | 423,114 | ||
BriaCell Therapeutics Corp. (BCTXZ)
BriaCell Therapeutics Corp. (BCTXZ)